SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Oppenheimer Maintains Outperform on Global Blood Therapeutics, Raises Price Target to $101

Oppenheimer maintains Global Blood Therapeutics (NASDAQ:GBT) with a Outperform and raises the price target from $88 to $101.

Benzinga · 05/07/2020 14:22

Oppenheimer maintains Global Blood Therapeutics (NASDAQ:GBT) with a Outperform and raises the price target from $88 to $101.